Dechra Competitors

Delisted . USA . 
Stock . Dechra Pharmaceuticals PLC
DPHAYDelisted Stock  USD 93.78  0.00  0.00%   
Dechra Pharmaceuticals competes with Pfizer, Sanofi ADR, Bristol Myers, AstraZeneca PLC, and Gilead Sciences; as well as few others. The company classifies itself under Healthcare sector and is part of Drug Manufacturers—General industry. Analyzing Dechra Pharmaceuticals competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Dechra Pharmaceuticals to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.
You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of Dechra Pharmaceuticals competition on your existing holdings.
  
Specify up to 10 symbols:
Hype
Prediction
LowEstimatedHigh
93.7893.7893.78
Details
Intrinsic
Valuation
LowRealHigh
76.6076.60103.16
Details
Naive
Forecast
LowNextHigh
93.7293.7293.72
Details
Bollinger
Band Projection (param)
LowerMiddle BandUpper
93.5293.7393.94
Details
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Dechra Pharmaceuticals. Your research has to be compared to or analyzed against Dechra Pharmaceuticals' peers to derive any actionable benefits. When done correctly, Dechra Pharmaceuticals' competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy toward taking a position in Dechra Pharmaceuticals.

Dechra Pharmaceuticals Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Dechra Pharmaceuticals and its competitors represents the degree of relationship between the price movements of corresponding pink sheets. A correlation of about +1.0 implies that the price of Dechra and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Dechra Pharmaceuticals does not affect the price movement of the other competitor.
Click cells to compare fundamentals   Check Volatility   Backtest Portfolio
High positive correlations   
NVS
+ 0.96
AZN
GSK
+ 0.95
MRK
MRK
+ 0.93
SNY
GSK
+ 0.91
SNY
MRK
+ 0.91
NVS
NVS
+ 0.9
SNY
  
High negative correlations   
GSK
- 0.93
BMY
MRK
- 0.92
BMY
GILD
- 0.89
AZN
BMY
- 0.89
SNY
NVS
- 0.88
BMY
AZN
- 0.88
BMY

Risk-Adjusted Indicators

There is a big difference between Dechra Pink Sheet performing well and Dechra Pharmaceuticals Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Dechra Pharmaceuticals' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
Mean DeviationJensen AlphaSortino RatioTreynor RatioSemi DeviationExpected ShortfallPotential UpsideValue @RiskMaximum Drawdown
PFE  0.99 (0.20) 0.00 (0.40) 0.00 
 0.00 
 2.17 
(2.45)
 8.17 
SNY  0.90 (0.22) 0.00 (2.27) 0.00 
 0.00 
 1.74 
(1.85)
 7.81 
BMY  1.31  0.33  0.15  3.11  1.18 
(1.47)
 2.23 
(2.07)
 14.39 
AZN  1.05 (0.40) 0.00  28.98  0.00 
 0.00 
 1.28 
(3.18)
 8.50 
GILD  0.91  0.22  0.11  0.57  1.00 
(0.95)
 2.17 
(1.82)
 10.80 
NVS  0.69 (0.22) 0.00 (0.88) 0.00 
 0.00 
 1.12 
(1.98)
 6.05 
MRK  0.85 (0.26) 0.00 (1.12) 0.00 
 0.00 
 1.73 
(2.13)
 4.89 
GSK  1.12 (0.34) 0.00 (0.96) 0.00 
 0.00 
 1.89 
(2.56)
 8.87 
AMGN  1.03 (0.25) 0.00 (0.13) 0.00 
 0.00 
 1.67 
(1.90)
 9.43 
ABBV  1.02 (0.16) 0.00 (0.72) 0.00 
 0.00 
 1.56 
(2.11)
 18.93 
All Fundamental Data

Dechra Pharmaceuticals Competitive Analysis

The better you understand Dechra Pharmaceuticals competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Dechra Pharmaceuticals' competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Dechra Pharmaceuticals' competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
DPHAY PFE SNY BMY AZN GILD NVS MRK GSK AMGN
 0.00 
 93.78 
Dechra
 2.07 
 25.65 
Pfizer
 0.63 
 48.28 
Sanofi
 1.10 
 58.87 
Bristol
 2.13 
 65.63 
AstraZeneca
 0.48 
 90.19 
Gilead
 0.41 
 104.28 
Novartis
 0.68 
 99.18 
Merck
 0.77 
 33.96 
GlaxoSmithKline
 1.60 
 294.53 
Amgen
Market Volatility
(90 Days Market Risk)
Very steady
Very steady
Very steady
Very steady
Very steady
Very steady
Very steady
Very steady
Very steady
Very steady
Market Performance
(90 Days Performance)
Very Weak
Very Weak
Very Weak
Good
Very Weak
Good
Very Weak
Very Weak
Very Weak
Very Weak
Odds of Financial Distress
(Probability Of Bankruptcy)
Dangerous
Below Average
Very Small
Low
Low
Very Low
Very Low
Low
Low
Low
Current Valuation
(Equity Enterprise Value)
Over Valued
Under Valued
Under Valued
Under Valued
Under Valued
Under Valued
Over Valued
Fairly Valued
Fairly Valued
Over Valued
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Buy
Strong Buy
Buy
Strong Buy
Buy
Buy
Strong Buy
Buy
Buy
Trade Advice
(90 Days Macroaxis Advice)
Not Rated
Strong Hold
Cautious Hold
Strong Buy
Strong Hold
Buy
Strong Hold
Cautious Hold
Strong Hold
Strong Hold
Current Ratio
2.91
1.59
1.3
1.42
0.81
1.43
1.31
1.46
1.43
1.68
Net Asset
1.29 B
226.5 B
126.46 B
95.16 B
101.12 B
62.12 B
99.94 B
106.67 B
59.01 B
97.15 B
Profit Margin
0.0854
0.0716
0.093
-0.15
0.13
0.0045
0.35
0.19
0.0802
0.13
EBITDA
178.9 M
9.56 B
12.6 B
19.42 B
12.98 B
7.61 B
18.29 B
6.91 B
9.08 B
7.9 B
Operating Margin
0.14
0.33
0.29
0.18
0.2
0.42
0.33
0.26
0.0833
0.24
Current Valuation
4.04 B
202.02 B
140.02 B
162.7 B
230.96 B
130.61 B
229.29 B
274.43 B
85.07 B
209.71 B
Price To Book
4.99
1.58
1.59
6.97
5.0
6.08
4.81
5.64
3.93
21.03
Retained Earnings
N/A
118.35 B
67.5 B
28.77 B
4.52 B
16.3 B
49.65 B
53.9 B
7.74 B
(26.55 B)
Current Asset
N/A
43.8 B
24.93 B
10.41 B
16.01 B
1.18 B
22.84 B
29.76 B
16.59 B
38.52 B
Five Year Return
N/A
3.6
3.85
2.96
2.99
3.76
3.53
2.99
5.32
2.82
Beta
0.68
0.62
0.45
0.44
0.18
0.19
0.51
0.41
0.33
0.6
Number Of Employees
2 K
88 K
86.09 K
34.1 K
89.9 K
18 K
76.06 K
70 K
70.21 K
26.7 K
Shares Outstanding
56.92 M
5.67 B
2.51 B
2.03 B
3.1 B
1.25 B
2 B
2.53 B
2.04 B
537.53 M
Cash Flow From Operations
122.9 M
8.7 B
10.26 B
13.86 B
10.35 B
8.01 B
14.46 B
13.01 B
6.77 B
8.47 B
Annual Yield
0.0148
0.0655
0.0422
0.0408
0.0226
0.0342
0.0362
0.0327
0.0461
0.0306
Total Debt
313.7 M
75.04 B
18.42 B
41.46 B
28.62 B
24.99 B
26.35 B
36.27 B
18.02 B
64.61 B
Return On Equity
0.0896
0.0454
0.0582
-0.31
0.17
0.0056
0.29
0.28
0.22
0.56
Z Score
7.8
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Return On Asset
0.0478
0.0331
0.0416
0.0607
0.085
0.12
0.11
0.11
0.0724
0.046
Book Value Per Share
12.3
16.29
58.1
8.45
26.27
14.83
21.67
17.58
3.43
14.0
Number Of Shares Shorted
N/A
61.87 M
8.12 M
23.42 M
4.63 M
17.74 M
4.76 M
26.23 M
16.29 M
8.82 M
Current Liabilities
N/A
29.4 B
16.82 B
8.02 B
14.87 B
104.89 M
23.71 B
19.2 B
13.42 B
8.67 B
Total Asset
1.29 B
226.5 B
126.46 B
95.16 B
101.12 B
62.12 B
99.94 B
106.67 B
59.01 B
97.15 B
Debt To Equity
0.5
0.4
0.3
1.32
0.89
1.3
0.47
0.68
0.98
N/A
Last Dividend Paid
0.45
1.67
N/A
2.4
2.97
3.06
3.92
3.04
0.61
8.88
Short Ratio
N/A
1.83
4.07
2.3
1.3
3.5
4.28
2.75
3.29
5.11
Target Price
N/A
32.55
63.49
59.37
88.27
96.89
116.16
130.85
45.95
334.06
Shares Owned By Institutions
0.09
67.79
11.64
78.41
16.75
88.37
6.75
79.46
15.38
81.09
Market Capitalization
4.3 B
145.36 B
121.05 B
119.4 B
203.49 B
112.4 B
211.15 B
250.89 B
69.29 B
158.32 B
Price To Earning
N/A
9.48
7.78
24.88
103.39
359.42
9.22
18.05
11.8
22.74
Price To Earnings To Growth
N/A
0.18
0.76
2.06
0.71
0.53
3.11
0.069
0.73
2.12
Price To Sales
5.65
2.45
2.5
2.52
3.97
3.97
4.23
3.97
2.21
4.87
Net Income
58.2 M
2.13 B
5.4 B
8.04 B
6.9 B
5.61 B
8.57 B
365 M
4.93 B
6.72 B
Earnings Per Share
1.29
0.75
1.88
-3.58
2.07
0.09
5.72
4.78
1.53
7.83
Shares Owned By Insiders
N/A
0.04
N/A
0.11
N/A
0.11
N/A
0.06
0.056
0.24
Revenue
681.8 M
58.5 B
46.03 B
45.01 B
45.81 B
27.12 B
46.66 B
60.12 B
30.33 B
28.19 B
Working Capital
N/A
(4.46 B)
6.46 B
9.51 B
(5.49 B)
4.8 B
4.09 B
6.47 B
(2.42 B)
11.94 B
Cash And Equivalents
123.7 M
2.85 B
6.9 B
9.12 B
4.52 B
6.14 B
4.64 B
12.69 B
3.72 B
11.48 B
Cash Per Share
2.29
6.44
2.76
6.21
1.46
4.9
8.84
4.44
0.32
21.51
Gross Profit
384.8 M
66.23 B
31.7 B
36.38 B
35.73 B
21.62 B
36.74 B
42.08 B
19.92 B
19.92 B
Day Typical Price
93.78
25.5
48.27
58.47
65.89
89.99
104.55
99.97
33.96
292.93
Accumulation Distribution
N/A
0.0252
0.0113
0.0221
0.0134
0.0133
0.0096
0.0281
0.0114
0.0227
Market Facilitation Index
N/A
0.65
0.55
1.3
0.89
1.2
1.01
2.86
0.39
6.7
Daily Balance Of Power
0.0
0.8
0.5455
0.4923
1.539326
0.3583
0.4257
(0.24)
0.6667
0.691
Period Momentum Indicator
N/A
0.52
0.3
0.64
1.37
0.43
0.43
(0.68)
0.26
4.63
Rate Of Daily Change
1.0
1.02
1.01
1.01
1.02
1.0
1.0
0.99
1.01
1.02
Day Median Price
93.78
25.43
48.27
58.27
66.01
89.89
104.69
100.36
33.96
292.13
Price Action Indicator
N/A
0.48
0.17
0.92
0.3
0.51
(0.19)
(1.52)
0.14
4.71
Relative Strength Index
67.18
33.21
34.4
57.55
16.76
87.54
29.89
25.66
36.78
53.65
Coefficient Of Variation
5226.92
(974.45)
(617.60)
550.66
(374.96)
493.19
(542.75)
(499.41)
(526.74)
(1,285)
Mean Deviation
0.8818
0.987
0.8982
1.31
1.05
0.9113
0.6853
0.8533
1.12
1.03
Jensen Alpha
0.0227
(0.20)
(0.22)
0.3339
(0.40)
0.2173
(0.22)
(0.26)
(0.34)
(0.25)
Total Risk Alpha
(0.44)
(0.37)
(0.40)
0.0375
(0.64)
0.0537
(0.34)
(0.42)
(0.54)
(0.38)
Sortino Ratio
N/A
N/A
N/A
0.1523
N/A
0.1107
N/A
N/A
N/A
N/A
Downside Variance
N/A
N/A
N/A
2.21
N/A
1.95
N/A
N/A
N/A
N/A
Standard Deviation
3.11
1.38
1.21
1.97
1.48
1.41
0.9732
1.14
1.53
1.57
Kurtosis
37.38
1.65
2.74
10.57
5.96
7.15
4.83
0.2024
3.15
7.1
Potential Upside
3.89
2.17
1.74
2.23
1.28
2.17
1.12
1.73
1.89
1.67
Treynor Ratio
0.2234
(0.40)
(2.27)
3.11
28.98
0.5725
(0.88)
(1.12)
(0.96)
(0.13)
Maximum Drawdown
25.27
8.17
7.81
14.39
8.5
10.8
6.05
4.89
8.87
9.43
Variance
9.68
1.9
1.47
3.87
2.2
1.98
0.9471
1.29
2.35
2.47
Market Risk Adjusted Performance
0.2334
(0.39)
(2.26)
3.12
28.99
0.5825
(0.87)
(1.11)
(0.95)
(0.12)
Risk Adjusted Performance
0.0222
(0.07)
(0.12)
0.1454
(0.20)
0.1601
(0.14)
(0.15)
(0.14)
(0.05)
Skewness
(4.93)
(0.13)
0.5331
2.19
(1.86)
1.0
(1.50)
0.2231
0.9933
(2.05)
Semi Deviation
N/A
N/A
N/A
1.18
N/A
0.9968
N/A
N/A
N/A
N/A
Information Ratio
(0.02)
(0.20)
(0.27)
0.1151
(0.35)
0.1099
(0.32)
(0.32)
(0.28)
(0.16)
Value At Risk
N/A
(2.45)
(1.85)
(2.07)
(3.18)
(1.82)
(1.98)
(2.13)
(2.56)
(1.90)
Expected Short fall
N/A
N/A
N/A
(1.47)
N/A
(0.95)
N/A
N/A
N/A
N/A
Downside Deviation
N/A
N/A
N/A
1.49
N/A
1.4
N/A
N/A
N/A
N/A
Semi Variance
N/A
N/A
N/A
1.39
N/A
0.9936
N/A
N/A
N/A
N/A

Dechra Pharmaceuticals Competition Performance Charts

Five steps to successful analysis of Dechra Pharmaceuticals Competition

Dechra Pharmaceuticals' competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Dechra Pharmaceuticals in relation to its competition. Dechra Pharmaceuticals' competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of Dechra Pharmaceuticals in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Dechra Pharmaceuticals' competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Dechra Pharmaceuticals, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your Dechra Pharmaceuticals position

In addition to having Dechra Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run SPAC Thematic Idea Now

SPAC
SPAC Theme
Entities that are involved in raising capital, merging with and acquiring companies, and investing in private equity through leveraged buyouts. The SPAC theme has 25 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize SPAC Theme or any other thematic opportunities.
View All  Next Launch
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.
You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.

Other Consideration for investing in Dechra Pink Sheet

If you are still planning to invest in Dechra Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Dechra Pharmaceuticals' history and understand the potential risks before investing.
Transaction History
View history of all your transactions and understand their impact on performance
Top Crypto Exchanges
Search and analyze digital assets across top global cryptocurrency exchanges
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
CEOs Directory
Screen CEOs from public companies around the world
AI Portfolio Architect
Use AI to generate optimal portfolios and find profitable investment opportunities
Economic Indicators
Top statistical indicators that provide insights into how an economy is performing
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY